Abstract:Purpose: Bone tissue is constantly remodeled. Abnormal osteoclast formation may result in bone disorders, such as osteoporosis, Paget’s disease, and rheumatoid arthritis. Nuclear factor of κB (NF-κB) plays a key role in osteoclast formation and bone resorption. A key event in NF-κB signaling is the activation of an adaptor protein TRAF6. Once activated, TRAF6 further activates IKKβ (I-κB kinase), which phosphorylates I-κBα (the inhibitor of NF-κB), leading to its degradation. Carboxyl terminus of Hsp70-interacting protein (CHIP) is an E3 ligase and regulates the stability of several proteins which are involved in tumor growth and metastasis. However, the role of CHIP in bone remodeling in vivo has not been reported. The objective of this study is to investigate the role of CHIP in regulation of bone mass and bone remodeling and determine the molecular mechanism of CHIP in regulation of TRAF6 protein stability. Methods: The bone phenotype of 1-month-old Chip-/- mice was examined by histology, histomorphometry, μCT, and gene expression analyses. The regulation of CHIP on TRAF6 degradation and the inhibition of NF-κB signaling was examined by immunoprecipitation, Western blotting, and ubiquitination assay. Results: In this study, we found that deletion of Chip leads to osteopenic phenotype. There was significant reduction in bone volume (%, BV/TV, 66% decrease) and bone mineral density (59% decrease) in Chip-/- mice. Trabecular numbers (44% decrease), trabecular thickness (33% decrease) were significantly decreased in Chip-/- mice. In contrast, trabecular separation (1.7-fold increase) was significantly increased in Chip-/- mice. Higher structure model index (1.4-fold increase) and lower connectivity density (75% decrease) were observed in Chip-/- mice, suggesting more fragile bone when Chip gene is deleted. Cortical bone volume (40% decrease) and bone mineral density (40% decrease) were also significantly reduced in Chip-/- mice. One major reason for the osteopenic phenotype observed in Chip-/- mice could be due to the increase in osteoclast formation. TRAP-positive osteoclast numbers (1.6-fold increase) and osteoclast surface (1.5-fold increase) were significantly increased in Chip-/- mice. In vitro osteoclast formation assay showed that there was 3.5-fold increase in osteoclast formation in Chip-/- mice using osteoclast precursor cells isolated from WT and Chip-/- mice. Consistently bone resorption area was also increased in Chip-/- mice, demonstrated by an in vitro bone resorption assay using bone marrow cells derived from WT and Chip-/- mice. The expression of osteoclast marker genes, such as Cathepsin K (7-fold increase), Mmp9 (16-fold increase), Trap (16-fold increase), and Nfatc1 (3-fold increase), was significantly increased after RANKL treatment in bone marrow cells derived from Chip-/- mice. There was a significant increase in TRAF6 protein levels in Chip-deficient bone marrow cells. In contract, no changes in TRAF6 mRNA levels were found in the same Chip-/- cells, suggesting that CHIP may regulate TRAF6 protein stability. In a series of in vitro studies we found that: 1) Interaction of endogenous CHIP with TRAF6 was detected in RAW264.7 osteoclast-like cells. 2) The ubiquitination of endogenous TRAF6 protein was reduced in Chip-/- bone marrow cells. 3) The phosphorylation of IKKα/β and IκBα was significantly increased in Chip-/- bone marrow cells after RANKL stimulation. 4) p65 nuclear translocation was enhanced in Chip-/- bone marrow cells when the cells were treated with RANKL. Conclusions: Our studies demonstrated that CHIP interacts with TRAF6 in osteoclast precursor cells and promotes TRAF6 ubiquitination and proteasome degradation; subsequently inhibits NF-κB signaling and regulates osteoclast formation. In Chip KO mice TRAF6 protein levels are increased, leading to activation of osteoclast formation and significant bone loss.

Type I Phosphotidylinosotol 4-Phosphate 5-Kinase Γ Regulates Osteoclasts in a Bifunctional Manner.

Gα13 Negatively Controls Osteoclastogenesis Through Inhibition of the Akt-GSK3β-NFATc1 Signalling Pathway

Loss of phosphatidylinositol-4-phosphate 5-kinase type-1 gamma (Pip5k1c) in mesenchymal stem cells leads to osteopenia by impairing bone remodeling

Pip5k1c expression in osteocytes regulates bone remodeling in mice

Type Iγ phosphatidylinositol phosphate kinase targets and regulates focal adhesions

PGC1β Organizes the Osteoclast Cytoskeleton by Mitochondrial Biogenesis and Activation

Inhibition of lipid kinase PIKfyve reveals a role for phosphatase Inpp4b in the regulation of PI(3)P-mediated lysosome dynamics through VPS34 activity

Novel Phosphatase PPM1H Controls BMP Signaling and Osteoblast Differentiation

Chip is A Critical Regulator of Traf6 Degradation and Osteoclast Formation

Cyclophilin D, regulator of the mitochondrial permeability transition, impacts bone development and fracture repair

KO of 5-Insp7 Kinase Activity Transforms the HCT116 Colon Cancer Cell Line into a Hypermetabolic, Growth-Inhibited Phenotype

Type I Phosphatidylinositol Phosphate Kinase Beta Regulates Focal Adhesion Disassembly by Promoting Beta 1 Integrin Endocytosis

Tgif1-deficiency impairs cytoskeletal architecture in osteoblasts by activating PAK3 signaling

Conditional knockout of the PDK‐1 gene in osteoblasts affects osteoblast differentiation and bone formation

Impact of the SIK3 Pathway Inhibition on Osteoclast Differentiation via Oxidative Phosphorylation

Regulation of Hematopoietic Cell Development and Function Through Phosphoinositides

Targeting osteoblastic casein kinase-2 interacting protein-1 to enhance Smad-dependent BMP signaling and reverse bone formation reduction in glucocorticoid-induced osteoporosis

Phospholipase C β4 promotes RANKL-dependent osteoclastogenesis by interacting with MKK3 and p38 MAPK

The P38 MAPK Pathway is Essential for Skeletogenesis and Bone Homeostasis in Mice.

ThPOK Inhibits Osteoclast Formation Via NFATc1 Transcription and Function